^
Association details:
| Biomarker: | PD-L1 expression + CD68 positive |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab in triple negative breast cancer (TNBC)
Published date:
07/24/2020
Excerpt:
Expression of PD-L1 in tumor cells, immune cells in stroma, and co-localized with CD68 positive cells is associated with higher rates of pCR to durvalumab and chemotherapy in TNBC.
Secondary therapy:
Chemotherapy
DOI:
10.1158/1078-0432.CCR-20-1303
Trial ID:
